Find Faculty
Home>Find Faculty>Mindy Simpson, MD

Mindy Simpson, MD

Assistant Professor
Department of Pediatrics, RUSH Medical College
Pronouns: 
She/Her
Education

MD, Temple University School of Medicine

Contact Info:

1725 W. Harrison St.
Suite 710
Chicago, IL 60612
Phone: (312) 942-3034
Fax: (312) 563-2317
Links:
Publications

http://www.ncbi.nlm.nih.gov/pubmed/?term=Simpson+ML%5BAuthor%5D

Grants
  • GENA 05, Immunogenicity, efficacy and safety of treatment with human-cl rhFVIII in previously untreated patients with severe hemophilia A, Role: PI
  • CSL Behring GmbH, Extension trial: safety and efficacy of CSL 627 in the treatment of hemophilia A”, Role: PI
  • GENA-21b, Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with human-cl rhFVIII in previously treated adult patients with severe haemophilia A”, Role: co-investigator
  • H13-21115/Investigator Initiated Research, Identification and monitoring of acute joint bleeding using ultrasonography and blood biomarkers, Role: co-PI
  • Hemophilia inhibitor research study (HIRS) — phase III inhibitor surveillance study, Role: PI
  • 998HB303, Open-label, multicenter evaluation of the safety and efficacy or recombinant, long-acting coagulation factor IX Fc fusion protein (rFIXFc) in the prevention and treatment of bleeding in previously untreated patients with severe hemophilia B, Role: PI
  • Project # CDC-RFA-DD11-1103, Public health surveillance prevention of complications of bleeding and clotting disorders, Role: co-investigator
  • COMMUNITY COUNTS -Registry for bleeding disorders surveillance, Sub I ATHN data set: portal submission for webtracker/clinical manager and the ATHN dataset, Role: co -investigator
  • ATHN2014-MLOF-2, My life, our future: genotyping for patients diagnosed with hemophilia A or B, Role: PI
  • 03-585, KidsDOTT, prospective multi-center evaluation of the duration of therapy for thrombosis in children, Role: PI
  • Prospective inceptional cohort study (PICS) of individuals with bleeding and clotting disorders, Role: PI
  • CSL627-3002, Hemophilia A pediatric study, Role: PI
  • RB-FVIIa-006-13, A phase 3 prospective, open-label, randomized, cross over study to evaluate safety, PK and efficacy of coagulation factor VIIa (recombinant) in congenital hem A/B with inhibitors to factor VIII/IX, Role: co-investigator
  • SelG1-00005, SUSTAIN: phase II, multicenter, randomized, placebo-controlled, double-blind, 12-mos. Study to assess safety and efficacy of SelG1 in sickle cell patients with sickle cell-related pain crisi, Role: PI
  • 997HA309, A randomized, open-label study to evaluate the PK and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc: BIIB031) manufactured at 15K scale and at vial strengths up to 6000IU in previously treated subjects with severe hemophilia A, Role: PI
  • Single dose FIH study, phase I/IIa clinical study assessing the safety, pharmacokinetics and pharmacodynamics of a long-acting recombinant factor VIIa (MOD-5014) in adult males, Role: co-investigator
  • CP-5-001, IDPH sickle cell grant, Role: PI
  • Healthcare shadow program, Role: PI